Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1998-03-18
2004-11-16
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S241100, C424S282100, C424S202100, C424S209100, C424S217100, C424S278100, C514S002600
Reexamination Certificate
active
06818222
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to adjuvants useful for the administration of antigens to organisms. In particular, the adjuvants of the invention allow the parenteral delivery of vaccines to raise an immune response.
BACKGROUND OF THE INVENTION
Advances in recombinant DNA technology have made possible the generation of a variety of vaccines, such as subunit vaccines and DNA-based vaccines. These are in addition to the more traditional killed or attenuated vaccines. Adjuvants that enhance the immune system's response to antigenic material are known; however, currently, few adjuvants are approved for human usage, although additional adjuvants are in pre-clinical and clinical studies.
The ADP-ribosylating bacterial toxins, a group of potent toxins to humans, include diphtheria toxin, pertussis toxin (PT), cholera toxin (CT), the
E. coli
heat-labile toxins (LT1 and LT2), Pseudomonas endotoxin A,
C. botulinum
C2 and C3 toxins, as well as toxins from
C. perfringens, C. spiriforma
and
C. difficile
. These toxins are composed of a monomeric, enzymatically active A subunit which is responsible for ADP-ribosylation of GTP-binding proteins, and a non-toxic B subunit which binds receptors on the surface of the target cell and delivers the A subunit across the cell membrane.
In the case of CT and LT, the A subunit is known to increase intracellular cAMP levels in target cells, while the B subunit is pentameric and binds to GM1 ganglioside receptors. (LT-B also binds additional receptors.)
Previously, observations were made demonstrating that CT is able to induce mucosal and systemic immunity against itself when administered intraduodenally (i.e. to a mucosal surface). The membrane-binding function of CT was shown to be essential for mucosal immunogenicity, but cholera toxoid, also known as the B subunit of CT (CT-B) was inactive in isolation (Pierce and Gowans,
J. Exp. Med.
1975; 142: 1550; Pierce,
J. Exp Med.
1978; 148: 195-206).
Subsequently, it was demonstrated that native CT induced immunity to co-administered antigens (Elson,
Curr. Top. Microbiol. Immunol.,
1989; 146:29; Blson and Ealding,
J. Immunol.
1984; 133:2892-2897; Elson and Ealding, Ibid. 1984; 132:2736-2741; Elson et al.,
J. Immunol. Meth.
1984; 67:101-118; Lycke and Homgren,
Immunology
1986; 59:301-339) and that immune responses may be elicted to diptheria or tetanus toxoids when these antigens are applied to skin in combination with CT.
Two approaches have been taken in order to address the problem of CT toxicity. The first approach has involved the use of CT-B as a mucosal adjuvant. CT-B is entirely non-toxic. An adjuvant effect for co-administered CT-B has been alleged in a number of publications (Tamura et al.,
J. Immunol.
1992; 149:981-988; Hirabayashi et al.,
Immunology
1992; 75: 493-498; Gizurarson et al.,
Vaccine
1991; 9:825-832; Kikuta et al.,
Vaccine
1970; 8:595-599; Hirabayashi et al. Ibid. 1990; 8:243-248; Tamura et al., Ibid. 1989; 7:314-32-; Tamura et al., Ibid. 1989; 7:257-262; Tamura et al., Ibid. 1988; 6:409-413; Hirabayashi et al.,
Immunology
1991; 72:329-335 Tamura et al.,
Vaccine
1989; 7:503-505).
However, a number of aspects of the observations reported above were not entirely convincing. For example, it was noted that the adjuvant effect ascribed to CT-B was not H-2 (MHC) restricted. It is known, however, that the immune response to CTB is H-2 (MHC) restricted (Elson and Ealding, Bur. J. Immuno. 1987; 17:425-428). Moreover, the alleged adjuvant effect was observed even in individuals already immune to CT-B.
Other groups were unable to observe any mucosal adjuvant effect attributable to CT-B (Lycke and Holmgren,
Immunology
1986; 59:301-308; Lycke et al.,
Eur. J. Immunol.
1992: 22:2277-2281). Experiments with recombinant CT-B (Holmgren et al.,
Vaccine
1993; 11:1179-1183) confirmed that the alleged effect is largely, if not exclusively, attributable to low levels of contamination of CT-B preparations with CT.
A second approach to eliminating the toxicity of CT has been to mutate the active holotoxin in order to reduce or eliminate its toxicity. The toxicity of CT resides in the A subunit and a number of mutants to CT and its homologue, LT, comprising point mutations in the A subunit, are known in the art. See, for example, International Patent Application WO92/19265. It is accepted in the art that CT and LT are generally interchangeable, showing considerable homology. ADP-ribosylating bacterial toxin mutants have been shown to act as mucosal adjuvants, see International Patent Application WO95/17211.
SUMMARY OF THE INVENTION
Accordingly, there remains a need for an active adjuvant which may be used to increase the immunogenicity of an antigen when administered parenterally, such as intramuscularly, subcutaneously, intravenously, transcutaneously or intradermally. The present invention provides for such parenteral adjuvants in the form of non-toxic ADP ribosylating bacterial toxins. It is demonstrated herein that such mutants, lacking toxicity, are active as parenteral adjuvants and produce high antibody titers and/or induction of cytotoxic T-lymphocytes (CTLs).
In one embodiment, then, the subject invention is directed to a parenteral adjuvant composition comprising a detoxified mutant of a bacterial ADP-ribosylating toxin as the parenteral adjuvant and at least one selected antigen.
In another embodiment, the invention is directed to a parenteral adjuvant composition comprising a detoxified mutant of a bacterial ADP-ribosylating toxin as the parenteral adjuvant and a pharmaceutically acceptable topical vehicle.
In yet another embodiment, the invention is directed to a parenteral adjuvant composition comprising a detoxified mutant of a bacterial ADP-ribosylating toxin as the parenteral adjuvant, a pharmaceutically acceptable topical vehicle and at least one selected antigen.
In another embodiment, the invention is directed to a method for making a parenteral adjuvant composition comprising combining a detoxified mutant of a bacterial ADP-ribosylating toxin as the parenteral adjuvant with at least one selected antigen.
In still a further embodiment, the invention is directed to a method of making a parenteral adjuvant composition comprising combining a detoxified mutant of a bacterial ADP-ribosylating toxin as the parenteral adjuvant with a pharmaceutically acceptable topical vehicle.
In another embodiment, the invention is directed to a method for immunizing a vertebrate subject comprising parenterally administering to the vertebrate subject an immunologically effective amount of
a) an adjuvant comprising a detoxified mutant of a bacterial ADP-ribosylating toxin in combination with a pharmaceutically acceptable vehicle; and
b) at least one selected antigen.
In particularly preferred embodiments, the non-toxic adjuvant is a detoxified mutant selected from the group consisting of cholera toxin (CT), pertussis toxin (PT), and an
E. coli
heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-S109, and PT-K9/G129.
These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
REFERENCES:
patent: 4328209 (1982-05-01), Finkelstein et al.
patent: 4428931 (1984-01-01), Tolman et al.
patent: 4666837 (1987-05-01), Harford et al.
patent: 4834975 (1989-05-01), Siadak et al.
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4925792 (1990-05-01), Rappuoli
patent: 4935364 (1990-06-01), Kaper et al.
patent: 5032398 (1991-07-01), Kaslow
patent: 5085862 (1992-02-01), Klein et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5221618 (1993-06-01), Klein et al.
patent: 5244657 (1993-09-01), Klein et al.
patent: 5332583 (1994-07-01), Klein et al.
patent: 5358868 (1994-10-01), Klein et al.
patent: 5427788 (1995-06-01), Rappuoli et al.
patent: 5433945 (1995-07-01), Klein et al.
patent: 5601827 (1997-02-01), Collier et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5747028 (1998-05-01), Calderwood et al.
patent: 5770203 (1998-06-01), Burnette et al.
patent: 5773600 (1998-0
Barchfeld Gail
Del Giudice Giuseppe
Rappuoli Rino
Blackburn Robert P.
Chiron Corporation
Devi S.
Hale Rebecca M.
Pasternak Dahna S.
LandOfFree
Detoxified mutants of bacterial ADP-ribosylating toxins as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detoxified mutants of bacterial ADP-ribosylating toxins as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detoxified mutants of bacterial ADP-ribosylating toxins as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3293486